Details for Patent: 8,389,578
✉ Email this page to a colleague
Which drugs does patent 8,389,578 protect, and when does it expire?
Patent 8,389,578 protects GOCOVRI and OSMOLEX ER and is included in two NDAs.
This patent has four patent family members in three countries.
Summary for Patent: 8,389,578
| Title: | Composition and method for treating neurological disease |
| Abstract: | The invention provides methods and compositions for treating or preventing neurological disorders. |
| Inventor(s): | Went; Gregory T. (Mill Valley, CA), Fultz; Timothy J. (Pleasant Hill, CA), Porter; Seth (San Carlos, CA), Meyerson; Laurence R. (Las Vegas, NV), Burkoth; Timothy S. (San Francisco, CA) |
| Assignee: | Adamas Pharmaceuticals, Inc (Emeryville, CA) |
| Application Number: | 11/286,448 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,389,578 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,389,578
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adamas Operations | GOCOVRI | amantadine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 208944-001 | Aug 24, 2017 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING IMMEDIATE RELEASE LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS | ⤷ Try a Trial | ||||
| Adamas Operations | GOCOVRI | amantadine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 208944-002 | Aug 24, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING IMMEDIATE RELEASE LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS | ⤷ Try a Trial | ||||
| Adamas Operations | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-001 | Feb 16, 2018 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF DRUG-INDUCED EXTRAPYRAMIDAL REACTIONS IN ADULT PATIENTS WITH PARKINSON'S DISEASE | ⤷ Try a Trial | ||||
| Adamas Operations | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-001 | Feb 16, 2018 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF PARKINSON'S DISEASE | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,389,578
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 2588296 | ⤷ Try a Trial | |||
| European Patent Office | 1845968 | ⤷ Try a Trial | |||
| European Patent Office | 2623099 | ⤷ Try a Trial | |||
| World Intellectual Property Organization (WIPO) | 2006058236 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
